OR WAIT null SECS
March 19, 2024
Orchard Therapeutics’ Lenmeldy (atidarsagene autotemcel) marks the first gene therapy approved in the US for treating children with metachromatic leukodystrophy.
March 15, 2024
Understanding how to apply phase-appropriate GMPs is crucial for achieving successful regulatory approval.
February 27, 2024
CSL will share access to Cytegrity, its proprietary stable production system for lentiviral vector production, with Genezen.
February 02, 2024
The milestone approval of a gene-edited therapeutic paves the way for gene-editing technologies.
January 31, 2024
The final guidance provides recommendations for developing gene therapy products incorporating genome editing of human somatic cells.
January 17, 2024
Charles River’s off-the-shelf rep/cap plasmids are intended to simplify gene therapy supply chains.
January 02, 2024
Revolutionary therapies restructure pharmaceutical manufacturing.
There are positive indications for future growth.
December 28, 2023
Tome Bioscience is facilitating the transition in biology from the editing phase to the cut-and-paste phase.
December 27, 2023
Andelyn Biosciences has been selected by Ultragenyx to manufacture UX111, that company’s gene therapy for treating Sanfilippo Syndrome.